Clinical Trial Detail

NCT ID NCT01497444
Title Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors North Central Cancer Treatment Group
Indications

liver cancer

kidney cancer

Therapies

Evofosfamide + Sorafenib

Age Groups: senior adult

No variant requirements are available.